Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Quantum X Labs launches Qatacomb research initiative for quantum security
Quantum X Labs has launched the "Qatacomb" initiative within its QuantumQ Security division to explore quantum-mechanical security architectures that give authorized users practical access. The goal is dynamically adjusting protection levels to operational requirements; the next phase includes theoretical validation, simulations and proof-of-concept tests on quantum hardware. Development focuses on security solutions for governments, defense, critical infrastructure and enterprises. The company points to expected market growth for quantum security from around USD 2.5 billion (2026) to about USD 9.8 billion by 2030. » More on de.investing.com
Quantum X Labs achieves better results with AI-powered decoder for quantum error correction
Quantum X Labs reports that its updated AI-powered decoder outperformed the benchmarks of the “Matching-Family” (Correlated-Matching, PyMatching) in tests on Google’s public surface-code dataset. The decoder was trained exclusively on synthetic data, which the company says supports its generalizability to real experimental syndrome data. Quantum X Labs plans to replicate the results, extend them to additional device and code configurations, and evaluate real hardware data as well as NVIDIA CUDA-Q–supported workflows in follow-up experiments. » More on de.investing.com
Quantum X Labs demonstrates quantum-assisted analysis of real clinical data
Quantum X Labs has completed a successful demonstration of a quantum-assisted analysis of real clinical trial data in its own quantum simulation environment. The platform, operated via the subsidiary CliniQuantum, enables quantum-optimized sampling for continuous probability distributions, processes data end-to-end within a single system, and is designed for high-dimensional biomedical datasets. The company plans to expand the supported datasets, optimize its quantum algorithms, and conduct performance studies to quantify the benefit for clinical research and precision medicine. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 256.73K | 86.73% |
| Gross profit | 139.32K | 59.05% |
| Net profit | 2.18M | 122.01% |
| EBITDA | -1.02M | 70.89% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €54.1M |
Number of shares | 13.34M |
52-week high/low | €6.65 - €0.83 |
| Dividends | No |
Beta | 2.43 |
P/E ratio | -23.50 |
PEG ratio | -0.49 |
P/B ratio | 2.61 |
P/S ratio | -22.39 |
Company profile
| Name | Quantum X Labs |
| CEO | Amihay Hadad |
| Employees | 21 |
Discover assets
Shareholders of Quantum X Labs also invest in the following assets
